BioXcel Therapeutics (BTAI) EBITDA (2017 - 2026)

BioXcel Therapeutics' EBITDA history runs 10 years deep, the most recent figure standing at -$10.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 1.23% year-over-year to -$10.2 million; the TTM figure through Mar 2026 stood at -$50.6 million (up 4.88% YoY), while the FY2025 annual figure was -$50.5 million, up 24.96% from the prior year.
• EBITDA was -$10.2 million for Q1 2026 at BioXcel Therapeutics, up from -$10.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.1 million in Q1 2025 to a low of -$52.9 million in Q4 2022.
• Historically, EBITDA has averaged -$27.0 million across 5 years, with a median of -$19.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA plunged 102.42% in 2022, then surged 68.34% in 2024.
• A 5-year view of EBITDA shows it stood at -$52.9 million in 2022, then jumped by 62.42% to -$19.9 million in 2023, then soared by 47.21% to -$10.5 million in 2024, then climbed by 2.01% to -$10.3 million in 2025, then grew by 0.57% to -$10.2 million in 2026.
• The last three EBITDA figures came in at -$10.2 million (Q1 2026), -$10.3 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.